By targeting the unmet medical niche, built on the solid technology platforms, Biosyngen has multiple immunotherapy pipelines to cover a wide range of indications.
To develop immunotherapies for virus-related cancers, the BioSyngen approach is anchored on world’s largest EBV-specific library, for which we own the exclusive intellectual property. This extensive resource is our first differentiator; we are one of the few CAR-T projects for virus-related cancers and focus on highly prevalent EBV antigens as our main target.
Our library contains molecular data on EBV expression profiles, the corresponding receptors, and their underlying genetic sequence—including differences among cancer subtypes and various populations such as Asian and Caucasian groups.
Our IDENTIFIER platform allows us to identify the most unique and suitable tumor antigens and perform fast screening of antibodies and T cell receptors (TCRs) against these antigens.
By utilizing the MSE-T platform, our smart immune cells can effectively attack difficult-to-treat solid tumors by better recognizing tumor specific antigens and overcoming immunosuppressive tumor microenvironment.
The proprietary SUPER-T platform allows safety enhancement of immunotherapies in general by conditional activation only in tumor microenvironment.
Synthesizing this wealth of information, our platform reengineers patient-derived T cells to express the TCR or CAR. Our GMP production facilities further expand the T cell army through state-of-the-art culturing methods.
When infused into the patient, the highly specific receptors enable detection and binding to the cancer cell, while importantly reducing the “on-target, off-tumor” toxicities that typically plague other immunotherapies. Taken together, this significantly boosts the clinical efficacy, reliability, and safety of BioSyngen therapeutics.
Compared to the thousands of CAR-T cell projects that already target liquid cancers, our approach stands out by addressing difficult-to-treat solid tumors—challenging the limits and expanding the scope of immunotherapy applications. As our library also contains patient HLA data, BioSyngen therapies can match with and serve a broader range of individuals, enabling the T cells to survive in the tumor microenvironment for long enough to recognize and lyse the cancer cells.
Moreover, other immune cells are recruited to generate a stronger anti-tumor response and offer better protection against any potential relapse.
BioSyngen’s patented CAR-T cell therapy is the first-of-its-kind against virus-related solid cancers, targeting EBV antigens and filling a critical gap in immuno-oncology.
Rooted in a patient-centric approach, BioSyngen generates highly potent immunotherapies that are fit for each individual and carry enhanced safety profiles.